An2 Therapeutics Stock Price Prediction
| ANTX Stock | USD 1.39 0.05 3.73% |
Oversold Vs Overbought
53
Oversold | Overbought |
EPS Estimate Next Quarter (0.26) | EPS Estimate Current Year (1.45) | EPS Estimate Next Year (1.16) | Wall Street Target Price 2.6667 | EPS Estimate Current Quarter (0.38) |
Using AN2 Therapeutics hype-based prediction, you can estimate the value of AN2 Therapeutics from the perspective of AN2 Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in AN2 Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying AN2 because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
AN2 Therapeutics after-hype prediction price | USD 1.38 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
AN2 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of AN2 Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
AN2 Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of AN2 Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in AN2 Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of AN2 Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
AN2 Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting AN2 Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on AN2 Therapeutics' historical news coverage. AN2 Therapeutics' after-hype downside and upside margins for the prediction period are 0.07 and 5.04, respectively. We have considered AN2 Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
AN2 Therapeutics is slightly risky at this time. Analysis and calculation of next after-hype price of AN2 Therapeutics is based on 3 months time horizon.
AN2 Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as AN2 Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AN2 Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with AN2 Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.39 | 3.66 | 0.01 | 0.00 | 11 Events / Month | 8 Events / Month | In about 11 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1.39 | 1.38 | 0.72 |
|
AN2 Therapeutics Hype Timeline
AN2 Therapeutics is presently traded for 1.39. The entity has historical hype elasticity of -0.01, and average elasticity to hype of competition of 0.0. AN2 is anticipated to decline in value after the next headline, with the price expected to drop to 1.38. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.72%, whereas the daily expected return is presently at 0.39%. The volatility of related hype on AN2 Therapeutics is about 39927.27%, with the expected price after the next announcement by competition of 1.39. About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.46. Some equities with similar Price to Book (P/B) outperform the market in the long run. AN2 Therapeutics recorded a loss per share of 1.99. The entity last dividend was issued on the 11th of January 2018. Given the investment horizon of 90 days the next anticipated press release will be in about 11 days. Check out AN2 Therapeutics Basic Forecasting Models to cross-verify your projections.AN2 Therapeutics Related Hype Analysis
Having access to credible news sources related to AN2 Therapeutics' direct competition is more important than ever and may enhance your ability to predict AN2 Therapeutics' future price movements. Getting to know how AN2 Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how AN2 Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| AVTE | Aerovate Therapeutics | (0.02) | 3 per month | 2.13 | 0.14 | 5.58 | (3.86) | 19.11 | |
| ADAG | Adagene | 0.02 | 5 per month | 0.00 | (0.04) | 8.30 | (9.52) | 37.93 | |
| ACRV | Acrivon Therapeutics, Common | (0.04) | 6 per month | 0.00 | (0.11) | 7.66 | (7.65) | 22.84 | |
| RZLT | Rezolute | (0.28) | 7 per month | 3.11 | 0.04 | 6.81 | (5.54) | 30.01 | |
| ANEB | Anebulo Pharmaceuticals | 0.03 | 5 per month | 0.00 | (0.02) | 8.85 | (11.48) | 76.00 | |
| MLYS | Mineralys Therapeutics, Common | 0.14 | 8 per month | 3.37 | 0.03 | 6.27 | (5.79) | 20.98 | |
| MOLN | Molecular Partners AG | (0.10) | 5 per month | 0.00 | (0.03) | 9.61 | (8.53) | 52.92 | |
| PHVS | Pharvaris BV | (0.23) | 5 per month | 2.98 | 0.06 | 7.76 | (6.02) | 21.41 | |
| PEPG | PepGen | 0.39 | 8 per month | 0.00 | (0.27) | 4.75 | (9.02) | 26.81 | |
| PMVP | Pmv Pharmaceuticals | (0.1) | 3 per month | 2.01 | (0.01) | 3.75 | (3.64) | 13.98 | |
| ELYM | Eliem Therapeutics | 0.25 | 4 per month | 0.00 | (0.20) | 6.21 | (9.35) | 34.87 | |
| MNOV | MediciNova | 0.05 | 7 per month | 4.17 | 0.12 | 14.50 | (8.50) | 61.30 |
AN2 Therapeutics Additional Predictive Modules
Most predictive techniques to examine AN2 price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for AN2 using various technical indicators. When you analyze AN2 charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About AN2 Therapeutics Predictive Indicators
The successful prediction of AN2 Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as AN2 Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of AN2 Therapeutics based on analysis of AN2 Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to AN2 Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to AN2 Therapeutics's related companies.
Story Coverage note for AN2 Therapeutics
The number of cover stories for AN2 Therapeutics depends on current market conditions and AN2 Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that AN2 Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about AN2 Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
AN2 Therapeutics Short Properties
AN2 Therapeutics' future price predictability will typically decrease when AN2 Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of AN2 Therapeutics often depends not only on the future outlook of the potential AN2 Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. AN2 Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 23.6 M | |
| Cash And Short Term Investments | 107.3 M |
Additional Tools for AN2 Stock Analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.